Long-Term Firocoxib Use in Horses.
Authors: Buzelato Carli Iuri, Fielding Langdon
Journal: Journal of veterinary internal medicine
Summary
# Long-Term Firocoxib Use in Horses: Laboratory Safety Profile Firocoxib is widely prescribed for chronic conditions such as osteoarthritis in geriatric horses, yet little evidence exists regarding its long-term haematological and biochemical safety in this population. Researchers conducted a retrospective comparative analysis of 79 horses receiving firocoxib over extended periods against 153 control horses, measuring complete blood count and serum biochemistry alongside signalment data, with linear regression used to correlate medication duration with laboratory abnormalities. Whilst horses on firocoxib were significantly older (median 19 years versus 15 years), they demonstrated only marginal laboratory differences: slightly elevated total protein (6.6 versus 6.5 g/dL), sodium (139 versus 138 mmol/L), and lower white blood cell counts (6.11 versus 6.46 × 10³ cells/µL)—all statistically significant but clinically modest. Notably, no laboratory variables showed correlation with duration of firocoxib administration, suggesting that prolonged use does not produce cumulative metabolic or haematological deterioration. For practitioners managing chronic pain in older horses, these findings provide reassurance that long-term firocoxib administration at therapeutic doses appears safe from a laboratory perspective, though individual clinical monitoring remains essential as this study does not preclude other adverse effects.
Read the full abstract on PubMed
Practical Takeaways
- •Long-term firocoxib use (years to multiple years) appears safe with minimal expected changes in routine bloodwork—expect only minor variations in protein, sodium, and WBC that are unlikely to be clinically significant
- •Osteoarthritis remains the primary indication (56% of cases); firocoxib-treated horses tend to be older animals, so age-related considerations should guide monitoring protocols
- •Routine laboratory monitoring during long-term firocoxib therapy does not need to focus on detecting drug-related hematologic or biochemical toxicity, allowing practitioners to concentrate on clinical signs and joint-specific assessments
Key Findings
- •Horses receiving long-term firocoxib were significantly older (median 19 years) compared to control group (median 15 years, p<0.0001)
- •Firocoxib-treated horses showed minimal but statistically significant differences in total protein (6.6 vs 6.5 g/dL, p=0.03) and sodium (139 vs 138 mmol/L, p=0.01) compared to controls
- •Total white blood cell count was slightly lower in firocoxib group (6.11 vs 6.46 ×10³ cells/µL, p=0.03)
- •No laboratory variables showed association with duration of firocoxib administration, suggesting long-term safety